Introduction BRCA1/2 mutation carriers are subjected to high rates of ovarian and breast cancer, thus recommendations for minimizing malignancy risk include risk reduction bilateral salpingo-oophorectomy (RRBSO), with or without hysterectomy and risk reduction mastectomy (RRM).

Methods This cross-sectional study was conducted by distribution of an anonymous questionnaire in social media platforms and BRCA1/2 mutation carriers medical clinic.

Results 530 BRCA1/2 mutation carriers answered the survey. RRBSO was discussed with 91% of patients and performed in 53%. Hormonal replacement therapy was discussed in 53% of patients. Addition of hysterectomy to RRBSO was discussed in 27% of patients and performed by 10%. Age over 35 years at time of mutation detection was found significant in raising RRBSO and hysterectomy performance rates. RRM was discussed in 83% of patients and performed in 33%. In a multivariate analysis, BRCA1 mutation carriers (OR 1.66 (95% CI 1.07–2.57) p=0.024) and a personal cancer history (OR 4.75 (95% CI 1.82–12.4) p=0.001) leading to the mutation detection were found significant in increasing the likelihood of opting RRM. Additionally, highest RRM performance rates were observed in the group of patients with a first-degree family history of breast cancer under the age of 50 years (OR 1.58 (95% CI 1.07–2.32) p=0.01).

Conclusion/Implications The data presented provides insights for the clinician counseling patients about their BRCA1/2 mutation, with not only explaining the risks and the acceptable recommendations, but also understanding their concerns and fears towards treatment and management alternatives and finally to construct a personalized management medical plan.